article thumbnail

Oncology dealmaking fuels biotech M&A

JD Supra: Mergers

Global spending on cancer medicines is set to reach US$375 billion by 2027, with innovation in drug discovery and development ramping up to meet rising demand. While the global biotech sector continues to grapple with elevated interest rates and plunging valuations, the oncology sector continues to attract dealmaker interest.

M&A 182
article thumbnail

The Dividend Discount Model (DDM): The Black Sheep of Valuation?

Mergers and Inquisitions

To be fair, in some industries – like commercial banks and insurance within FIG – the DDM is a core valuation methodology. And Equity Real Estate Investment Trusts (REITs) must distribute almost all their Net Income, so the DDM can work well in REIT valuations. The post The Dividend Discount Model (DDM): The Black Sheep of Valuation?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Food and Beverage Industry: Dairy Sector Spotlight

Focus Investment Banking

CAGR through 2027. Earlier reports indicated 15 billion euros as a ballpark valuation of the ice cream business. This growth is driven by rising consumer demand for indulgent treats and innovative product offerings. The take-home segment dominates, accounting for $17 billion of the market.

Food 52
article thumbnail

The 10 Benefits Software Modernization for SaaS Growth or Acquisition

Software Equity Group

trillion by 2027. As such, it enhances your potential to realize your exit strategy and achieve an attractive valuation in the M&A market. #1. In this session, we will review what parts of your company are market-ready and identify areas for improvement to maximize your valuation. Sign up for your Strategic Assessment.

article thumbnail

Cooley’s 2023 Cross-Border M&A Year in Review: Navigating Choppy Waters into a More Buoyant 2024

Cooley M&A

The higher interest rates escalated borrowing expenses, making mega-deals (deals valued at $5 billion or more) significantly more expensive, due to their heavy reliance on debt financing, and impacted valuation multiples with higher discount rates.

M&A 52